Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
gptkb:rituximab
gptkb:azacitidine gptkb:decitabine low-dose cytarabine |
| gptkbp:ATCCode |
L01XX52
|
| gptkbp:blackBoxWarning |
gptkb:tumor_lysis_syndrome
|
| gptkbp:brand |
gptkb:Venclyxto
|
| gptkbp:CASNumber |
1257044-40-8
|
| gptkbp:chemicalFormula |
C45H50ClN7O7S
|
| gptkbp:contraindication |
strong CYP3A inhibitors
|
| gptkbp:developer |
gptkb:AbbVie
gptkb:Genentech |
| gptkbp:FDAapprovalDate |
2016
|
| gptkbp:genericName |
gptkb:venetoclax
|
| https://www.w3.org/2000/01/rdf-schema#label |
Venclexta
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
BCL-2 inhibitor
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea diarrhea neutropenia thrombocytopenia |
| gptkbp:usedFor |
gptkb:small_lymphocytic_lymphoma
gptkb:acute_myeloid_leukemia chronic lymphocytic leukemia |
| gptkbp:bfsParent |
gptkb:AbbVie
gptkb:Roche |
| gptkbp:bfsLayer |
6
|